WallStreetZenWallStreetZen

NASDAQ: KYMR
Kymera Therapeutics Inc Stock

$42.47-0.63 (-1.46%)
Updated Jul 22, 2024
KYMR Price
$42.47
Fair Value Price
-$29.55
Market Cap
$2.61B
52 Week Low
$9.60
52 Week High
$48.70
P/E
-16.92x
P/B
3.66x
P/S
35.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$79.41M
Earnings
-$154.59M
Gross Margin
100%
Operating Margin
-194.4%
Profit Margin
-194.7%
Debt to Equity
0.22
Operating Cash Flow
-$98M
Beta
1.57
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KYMR Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KYMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KYMR ($42.47) is overvalued by 243.73% relative to our estimate of its Fair Value price of -$29.55 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KYMR ($42.47) is not significantly undervalued (243.73%) relative to our estimate of its Fair Value price of -$29.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KYMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KYMR due diligence checks available for Premium users.

Be the first to know about important KYMR news, forecast changes, insider trades & much more!

KYMR News

Valuation

KYMR fair value

Fair Value of KYMR stock based on Discounted Cash Flow (DCF)
Price
$42.47
Fair Value
-$29.53
Undervalued by
243.80%
KYMR ($42.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KYMR ($42.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KYMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KYMR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-16.92x
Industry
-27.86x
Market
29.85x

KYMR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.66x
Industry
6.3x
KYMR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KYMR's financial health

Profit margin

Revenue
$10.3M
Net Income
-$48.6M
Profit Margin
-472%
KYMR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KYMR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$868.3M
Liabilities
$157.0M
Debt to equity
0.22
KYMR's short-term assets ($537.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KYMR's short-term assets ($537.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KYMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$39.6M
Investing
-$330.6M
Financing
$353.8M
KYMR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KYMR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KYMR$2.61B-1.46%-16.92x3.66x
PTCT$2.53B+1.23%-4.30x-2.83x
VCEL$2.51B+2.93%N/A10.72x
AGIO$2.71B+2.45%-7.56x3.64x
SWTX$2.73B-2.36%-7.15x4.81x

Kymera Therapeutics Stock FAQ

What is Kymera Therapeutics's quote symbol?

(NASDAQ: KYMR) Kymera Therapeutics trades on the NASDAQ under the ticker symbol KYMR. Kymera Therapeutics stock quotes can also be displayed as NASDAQ: KYMR.

If you're new to stock investing, here's how to buy Kymera Therapeutics stock.

What is the 52 week high and low for Kymera Therapeutics (NASDAQ: KYMR)?

(NASDAQ: KYMR) Kymera Therapeutics's 52-week high was $48.70, and its 52-week low was $9.60. It is currently -12.79% from its 52-week high and 342.4% from its 52-week low.

How much is Kymera Therapeutics stock worth today?

(NASDAQ: KYMR) Kymera Therapeutics currently has 61,358,262 outstanding shares. With Kymera Therapeutics stock trading at $42.47 per share, the total value of Kymera Therapeutics stock (market capitalization) is $2.61B.

Kymera Therapeutics stock was originally listed at a price of $33.26 in Aug 21, 2020. If you had invested in Kymera Therapeutics stock at $33.26, your return over the last 3 years would have been 27.69%, for an annualized return of 8.49% (not including any dividends or dividend reinvestments).

How much is Kymera Therapeutics's stock price per share?

(NASDAQ: KYMR) Kymera Therapeutics stock price per share is $42.47 today (as of Jul 22, 2024).

What is Kymera Therapeutics's Market Cap?

(NASDAQ: KYMR) Kymera Therapeutics's market cap is $2.61B, as of Jul 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kymera Therapeutics's market cap is calculated by multiplying KYMR's current stock price of $42.47 by KYMR's total outstanding shares of 61,358,262.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.